Stocktoria
Amphastar Pharmaceuticals, Inc. AMPH
Amphastar Pharmaceuticals, Inc. (AMPH) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $719.9M at a 13.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.62 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.293 |
| Retained earnings / assets | 0.409 |
| EBIT / assets | 0.086 |
| Equity / liabilities | 0.939 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| AMPH | Amphastar Pharmaceuticals, Inc. | 6/9 | 4.82 | 9.8 | -1.7% |
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | 3/9 | 5.11 | — | +8.6% |
| PCRX | Pacira BioSciences, Inc. | 8/9 | 3.08 | 141.1 | +3.6% |
| EBS | Emergent BioSolutions Inc. | 6/9 | 3.44 | 8.4 | -28.8% |
| CORT | CORCEPT THERAPEUTICS INC | 4/9 | 8.97 | 94.1 | +12.8% |
| KNSA | Kiniksa Pharmaceuticals International, plc | 6/9 | 5.08 | 77.2 | +60.1% |
| RARE | Ultragenyx Pharmaceutical Inc. | 4/9 | -9.61 | — | +20.2% |
About Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
FAQ
Is AMPH financially healthy?
Amphastar Pharmaceuticals, Inc.'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does AMPH pay a dividend?
No, Amphastar Pharmaceuticals, Inc. does not currently pay a dividend.
How profitable is AMPH?
In FY2025, Amphastar Pharmaceuticals, Inc. had a net margin of 13.6% and a return on equity of 12.4%.
Is AMPH overvalued or undervalued?
Amphastar Pharmaceuticals, Inc. trades at about 9.8× trailing earnings — below its 10-year norm (10-year range 11.4×–606.0×, median 19.3×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for AMPH?
The average Wall-Street price target for Amphastar Pharmaceuticals, Inc. is $22.00, about 10.1% above the recent price, from 6 analysts (consensus: hold).
Is AMPH a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Amphastar Pharmaceuticals, Inc.: a Piotroski F-score of 6/9, an Altman Z″ in the safe zone, a P/E of about 9.8×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.